You are viewing the site in preview mode
Skip to main content
|
Valuables
|
Group A (n = 110)
|
Group B (n = 90)
|
P value
|
|---|
|
Follow-up time (months)
|
95.9 ± 22.7
|
91.2 ± 20.8
|
0.130
|
|
Cerebral hemorrhage (%)
|
0 (0.0)
|
3 (3.3)
|
0.191
|
|
Cerebral infarction (%)
|
0 (0.0)
|
1 (1.1)
|
0.948
|
|
Gastrointestinal hemorrhage (%)
|
1 (0.9)
|
4 (4.4)
|
0.268
|
|
AR (moderate or above) (%)
|
2 (1.8)
|
0 (0.0)
|
0.590
|
|
Perivalvular leakage (%)
|
0 (0.0)
|
1 (1.1)
|
0.948
|
|
Biological valve aging (%)
|
0 (0.0)
|
0 (0.0)
|
N/A
|
|
Infection (%)
|
1 (0.9)
|
2 (2.2)
|
0.879
|
|
Mechanical disturbance of the valve (%)
|
0 (0.0)
|
3 (3.3)
|
0.191
|
|
endoleakage (%)
|
0 (0.0)
|
6 (6.7)
|
0.022
|
|
Anticoagulation-related thromboembolism/bleeding events* (%)
|
0 (0.0)
|
10 (11.1)
|
0.001
|
|
Postoperative aortic valve re-operation (%)
|
1 (0.9)
|
8 (8.9)
|
0.020
|
- Continuous variables were present as median (Q25, Q75) or mean ± SD. Chi-square test for categorical variables and t test or wilcoxon rank sum test for continuous variables
- Bold letters indicate a statistically significant difference
- *Anticoagulation-related thromboembolism/bleeding events include cerebral hemorrhage, gastrointestinal hemorrhage, mechanical flap stuck event, cerebral infarction, myocardial infarction, because of coagulation function was abnormal
